{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-017102","form_type":"8-K","ticker":null,"cik":"0001506928","company_name":"Avinger Inc","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.728918+00:00","generated_at":"2026-06-01T22:58:08.095673+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Avinger Q1 2024 revenue flat at $1.9M; gross margin drops to 18%, net loss widens to $5.5M","bullets":["Revenue $1.9M unchanged YoY and QoQ; gross margin fell to 18% from 34% in Q1 2023.","Net loss of $5.5M vs $4.6M in Q1 2023; operating expenses rose to $5.4M.","Secured up to $15M equity funding from Zylox-Tonbridge; $7.5M funded in March 2024.","Initiated Phase III studies for coronary CTO-crossing system; IDE submission expected Q3 2024.","Exchanged $61M Series A preferred stock for new Series A-1 with $10M value and no liquidation preference."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-017102","json":"https://secwatch.observer/filing/0001437749-24-017102.json","markdown":"https://secwatch.observer/filing/0001437749-24-017102.md","text":"https://secwatch.observer/filing/0001437749-24-017102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506928/000143774924017102/0001437749-24-017102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506928/000143774924017102/avgr20240514_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:58:08.095673+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aac9787a3ecdfd7a9e298011d3c542c5d2abaab9","claim":"Avinger Inc reported first quarter ended March 31, 2024 results: revenue $1.9 million, net income $5.5 million.","evidence_excerpt":"treatment of vascular disease, today reported results for the first quarter ended March 31, 2024. First Quarter and Recent Highlights ● Reported first quarter 2024 revenue of $1.9 million, and gross margin of 18% ● Continued full commercial launch of Tigereye ST, Avinger’s most advanced image-guided peripheral CTO-crossing device, and limited launch of the new","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506928/000143774924017102/0001437749-24-017102-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$1.9 million"},{"label":"Net income","value":"$5.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}